期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Siva-1在胃癌组织中的表达及其临床意义 被引量:2
1
作者 孔凡彪 邓洪强 +3 位作者 徐胜 王晓通 麦威 庞黎明 《中国现代医学杂志》 CAS 北大核心 2021年第6期1-4,共4页
目的探讨Siva-1在胃癌组织中的表达及其与细胞凋亡的关系。方法选取2016年1月—2018年12月广西壮族自治区人民医院经手术切除的胃癌组织及癌旁组织各54例。采用qRT-PCR和SP法检测Siva-1mRNA及蛋白的表达水平,分析Siva-1在胃癌组织中的... 目的探讨Siva-1在胃癌组织中的表达及其与细胞凋亡的关系。方法选取2016年1月—2018年12月广西壮族自治区人民医院经手术切除的胃癌组织及癌旁组织各54例。采用qRT-PCR和SP法检测Siva-1mRNA及蛋白的表达水平,分析Siva-1在胃癌组织中的表达及与临床病理特征的关系。结果胃癌组织中Siva-1阳性表达率较低(P <0.05),Siva-1 m RNA相对表达量较低(P <0.05)。不同肿瘤直径、肿瘤分期患者Siva-1阳性表达率比较,差异有统计学意义(P <0.05)。经Pearson相关性分析,Siva-1 mRNA表达量与肿瘤直径呈负相关(r=-0.376,P <0.05)。结论 Siva-1在胃癌组织中低表达,且与肿瘤的发生、发展有关,可作为诊断胃癌的潜在标志物。 展开更多
关键词 胃肿瘤 Siva-1/凋亡诱导因子 肿瘤标记 生物学
下载PDF
Reversal of multidrug resistance in gastric cancer cells by CDX2 downregulation 被引量:10
2
作者 Lin-Hai Yan Xiao-Tong Wang +6 位作者 Jie Yang Chao Lian fan-biao kong Wei-Yuan Wei Wen Luo Qiang Xiao Yu-Bo Xie 《World Journal of Gastroenterology》 SCIE CAS 2013年第26期4155-4165,共11页
AIM: To explore the role of CDX2 in the multi-drug resistance (MDR) process of gastric cancer in vitro and in vivo . METHODS: A cisplatin-resistant gastric cancer cell line with stable downregulation of CDX2 was estab... AIM: To explore the role of CDX2 in the multi-drug resistance (MDR) process of gastric cancer in vitro and in vivo . METHODS: A cisplatin-resistant gastric cancer cell line with stable downregulation of CDX2 was established. mRNA and protein expression levels of CDX2, survivin, cyclin D1, and c-Myc were detected by western blotting and semi-quantitative reverse-transcriptase polymerase chain reaction (RT-PCR). The influence of downregulation of CDX2 on MDR was assessed by measuring IC50 of SGC7901/DDP cells to cisplatin, doxorubicin, and 5-fluorouracil, rate of doxorubicin efflux, apoptosis, and cell cycle progression detected by flow cytometry. In addition, we determined the in vivo effects of CDX2 small interfering RNA (siRNA) on tumor size, and apoptotic cells in tumor tissues were detected by deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling and hematoxylin and eosin staining. RESULTS: CDX2 siRNA led to downregulation of endogenous CDX2 mRNA (0.31 ± 0.05 vs 1.10 ± 0.51, 0.31 ± 0.05 vs 1.05 ± 0.21, P = 0.003) and protein (0.12 ± 0.08 vs 0.51 ± 0.07, 0.12 ± 0.08 vs 0.55 ± 0.16, P = 2.57 × 10 -4) expression. It significantly promoted the sensitivity of SGC7901/DDP cells to cisplatin (0.12 ± 0.05 vs 0.33 ± 0.08, 0.12 ± 0.05 vs 0.39 ± 0.15, P = 0.001), doxorubicin (0.52 ± 0.13 vs 4.11 ± 1.25, 0.52 ± 0.13 vs 4.05 ± 1.44, P = 2.81 × 10-4), and 5-fluorouracil (0.82 ± 0.13 vs 2.81 ± 0.51, 0.82 ± 0.13 vs 3.28 ± 1.03, P = 1.71 × 10-4). Flow cytometry confirmed that the percentage of apoptotic cells increased after CDX2 downregulation (32.15% ± 2.15% vs 17.63% ± 3.16%, 32.15% ± 2.15% vs 19.3% ± 2.25%, P = 1.73 × 10-6). This notion was further supported by the observation that downregulation of CDX2 blocked entry into the S-phase of the cell cycle (31.53% ± 3.78% vs 65.05% ± 7.25%, 31.53% ± 3.78% vs 62.27% ± 5.02%, P = 7.55 × 10-7). Furthermore, downregulation of CDX2 significantly increased intracellular accumulation of doxorubicin (0.21 ± 0.06 vs 0.41 ± 0.11, 0.21 ± 0.06 vs 0.40 ± 0.08, P = 0.003). In molecular studies, semiquantitative RT-PCR and western blotting revealed that CDX2 downregulation could inhibit expression of c-Myc, survivin and cyclin D1. CONCLUSION: CDX2 may be involved in regulating multiple signaling pathways in reversing MDR, suggesting that CDX2 may represent a novel target for gastric cancer therapy. 展开更多
关键词 HOMEOBOX gene CDX2 RNA interference Gastric cancer Drug resistance Murine model
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部